MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call

Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S. & Canada)

Conference ID: 1391457

Webcast

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xa2m5uy7.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Investor Contact

917-362-1370

investor@minktherapeutics.com

Media Contact

781-674-4428

communications@minktherapeutics.com

Staff

Recent Posts

This World Cancer Day, St. Baldrick’s Foundation Leads the Charge Against Childhood Cancer

Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St.…

2 hours ago

The Leadership Shift Powering Doceree’s Next Chapter in the US: Kamya Elawadhi Announced as Co-Founder & President

Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…

4 hours ago

Canvas Medical Named 2026 Best in KLAS for Ambulatory Specialty EHR

Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…

4 hours ago

Kontakt.io Introduces Supply Chain AI to Transform Care Support Operations

Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…

4 hours ago

Robotic Surgery Market Is No Longer a Technology Story. It Is a Discipline Test for Hospitals: MMR Statistics

PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…

4 hours ago

Champion Insights Officially Opens Enrollment to Investigate ALS Risk in High-Performance Athletes, Military Members, and First Responders

Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…

4 hours ago